Osaic Holdings
ELVN icon

Osaic Holdings’s Enliven Therapeutics ELVN Stock Holding History

Osaic Holdings’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$528K Buy
10,397
+365
+4% +$15.5K ﹤0.01% 3625
2026
Q1 		$393K Buy
10,032
+9,972
+16,620% +$276K ﹤0.01% 3582
2025
Q4 		$924 Sell
60
-25
-29% -$498 ﹤0.01% 7300
2025
Q3 		$1.74K Sell
85
-64
-43% -$1.29K ﹤0.01% 7175
2025
Q2 		$2.99K Buy
+149
New +$2.82K ﹤0.01% 6797
2024
Q3 		– Sell
-15
Closed -$351 – 7443
2024
Q2 		$351 Sell
15
-1,985
-99% -$41.8K ﹤0.01% 7074
2024
Q1 		$35.2K Hold
2,000
– – ﹤0.01% 4979
2023
Q4 		$27.7K Hold
2,000
– – ﹤0.01% 5305
2023
Q3 		$27.3K Buy
2,000
+1,000
+100% +$16.8K ﹤0.01% 5382
2023
Q2 		$20.4K Buy
+1,000
New +$20.2K ﹤0.01% 5550

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Osaic Holdings's ELVN Position: Q2 2026 in Review

Osaic Holdings increased its Enliven Therapeutics (ELVN) stake by 3.6% in Q2 2026, buying an estimated $15.5K and bringing the position to 10,397 shares worth $528K. The position accounts for ﹤0.01% of the portfolio, ranked #3625.

Osaic Holdings first reported a position in ELVN in Q2 2023 and has held it in 10 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Osaic Holdings held 10,397 shares of Enliven Therapeutics worth $528K as of Q2 2026.
  • Osaic Holdings bought 365 Enliven Therapeutics shares in Q2 2026, an estimated $15.5K.
  • Enliven Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #3625 holding.
  • Osaic Holdings first reported a position in Enliven Therapeutics in Q2 2023 and has held it in 10 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.